Anakinra May Help Ease the Pain of Rheumatoid Arthritis
En Español (Spanish Version)


Anakinra (Kineret) is used to treat adults with pain and swelling caused by moderate to severe active rheumatoid arthritis (RA) who have not found relief from other treatments.

How Does Anakinra Work?
Anakinra blocks the action of the protein interleukin-1 (IL-1). IL-1 is produced in excessive amounts in people with RA. High levels of IL-1 contribute to the joint pain, swelling, and stiffness of RA. By blocking IL-1, anakinra can help reduce these symptoms.

You may need to take anakinra for several weeks before your RA symptoms begin to improve.

How Should I Take This Medication?
Anakinra is given once a day as an injection. If you are prescribed anakinra, a member of your healthcare team will teach you how to give yourself the injection so that you can do it at home.

What Are the Side Effects?
The main side effect of this drug is mild redness, swelling, and pain at the injection site. Other side effects include:

  • Infections (anakinra suppresses the immune system)
  • Headache
  • Nausea
  • Diarrhea
  • Flu-like symptoms
  • Abdominal pain
  • Low white blood cell count
Who Should Not Take Anakinra?
Anakinra is not for everyone with RA. Talk to your doctor before taking anakinra if you:

  • Have a fever or think you may have an infection
  • Are taking certain medications, including tumor necrosis factor (TNF) blockers, such as adalimumab, etanercept, or infliximab
  • Are allergic to proteins made from bacteria cells or any ingredient in the medication
  • Have a latex allergy
  • Have asthma, HIV infection, or kidney disease
  • Are pregnant or breastfeeding
If you are prescribed anakinra, there are other precautions that you should take, such as:

  • Telling your doctor or dentist that you are taking anakinra before you have a procedure
  • Talking to your doctor before you have a live virus vaccine
If you have tried other RA medications and have not had any relief from your symptoms, talk to your doctor to find out if anakinra is a good option for you.




RESOURCES:
Arthritis Foundation

US Food and Drug Administration

CANADIAN RESOURCES:
The Arthritis Society

Canadian Pharmacists Association

References
Anakinra. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated June 4, 2013. Accessed October 13, 2014.

Biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated October 8, 2014. Accessed October 13, 2014.

Bresnihan, B, Alvara-Gracia, JM, Cobby, M, et al. Treatment of rheumatoid arthritis with recombinant human IL-1 receptor antagonist. Arthritis Rheum. 1998; 41:2196.

Fleischmann, RM, Schechtman, J, Bennett, R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003; 48:927.

Last Reviewed September 2014



Health Information Library content is provided by EBSCO Publishing, fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.

 

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

 

To send comments or feedback to EBSCO's Editorial Team regarding the content please e-mail healthlibrarysupport@ebscohost.com.